Arbutus Biopharma Corp Deferred Revenue
Arbutus Biopharma Corp (ABUS) had Deferred Revenue of $1.72 million as of 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2018-05-04
- 2012-12-10: Deferred Revenue 3.23M CAD.
CAD
| Period end | Deferred Revenue |
|---|---|
| 2012-12-10 | 3.23M CAD 20-F · filed 2013-03-27 |
USD
| Period end | Deferred Revenue |
|---|---|
| 2018-03-31 | $1.72M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $2.74M 10-Q · filed 2018-05-04 |
| 2017-06-30 | $6.75M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $7.41M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $15.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $15.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $711.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $924.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $1.08M 10-K · filed 2017-03-22 |
| 2015-09-30 | $11.72M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $13.65M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $13.13M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $15.72M 10-K · filed 2016-03-09 |
| 2014-09-30 | $14.95M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $16.55M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $15.62M 10-Q · filed 2014-05-14 |
| 2013-12-31 | $3.46M 10-K · filed 2015-03-13 |
| 2012-12-10 | $3.00M 20-F · filed 2013-03-27 |
| 2010-05-10 | $3.00M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |